Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

• Status: Recruiting
• Trial end date: 2025-12-31

Summary

An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)

• Phase: Phase 3

Details

• Lead Sponsor: GWT-TUD GmbH
• Collaborator: Hoffmann-La Roche
• Treatments: Carboplatin; Etoposide; Ifosfamide; Rituximab